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Abstract
Glycogen synthase kinase-3b (GSK3b) is highly abundant in the brain. Various biochemical analyses have indicated that
GSK3b is localized to different intracellular compartments within brain cells. However, ultrastructural visualization of this
kinase in various brain regions and in different brain cell types has not been reported. The goal of the present study was to
examine GSK3b distribution and subcellular localization in the brain using immunohistochemistry combined with light and
electron microscopy. Initial examination by light microscopy revealed that GSK3b is expressed in brain neurons and their
dendrites throughout all the rostrocaudal extent of the adult mouse brain, and abundant GSK3b staining was found in the
cortex, hippocampus, basal ganglia, the cerebellum, and some brainstem nuclei. Examination by transmission electron
microscopy revealed highly specific subcellular localization of GSK3b in neurons and astrocytes. At the subcellular level,
GSK3b was present in the rough endoplasmic reticulum, free ribosomes, and mitochondria of neurons and astrocytes. In
addition GSK3b was also present in dendrites and dendritic spines, with some postsynaptic densities clearly labeled for
GSK3b. Phosphorylation at serine-9 of GSK3b (pSer9GSK3b) reduces kinase activity. pSer9GSK3b labeling was present in all
brain regions, but the pattern of staining was clearly different, with an abundance of labeling in microglia cells in all regions
analyzed and much less neuronal staining in the subcortical regions. At the subcellular level pSer9GSK3b labeling was
located in the endoplasmic reticulum, free ribosomes and in some of the nuclei. Overall, in normal brains constitutively
active GSK3b is predominantly present in neurons while pSer9GSK3b is more evident in resting microglia cells. This visual
assessment of GSK3b localization within the subcellular structures of various brain cells may help in understanding the
diverse role of GSK3b signaling in the brain.
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Introduction
Glycogen synthase kinase-3b (GSK3b) is a ubiquitous enzyme
which is found in nearly all mammalian tissues. However, it is
highly abundant in the brain [1]. GSK3b was originally shown to
phosphorylate and inhibit glycogen synthase. However, the last
decade has witnessed a resurgent interest in this enzyme because it
has been shown to be dysregulated in numerous pathologies.
Much attention has been focused on GSK3b signaling in the brain
due to its involvement in neurologic and psychiatric diseases. For
example, unregulated GSK3b activity appears to underlie the
pathogenesis of Alzheimer’s disease [2–5], Parkinson’s disease
[6,7], and Huntington’s disease [8]. In addition, anomalous
GSK3b signaling has been reported in psychiatric diseases,
including bipolar disorder [9,10] and schizophrenia [11,12]. Due
to its involvement in many brain disorders, it has become apparent
that normal GSK3b signaling is necessary to maintain brain
homeostasis.
The overall levels of GSK3b in the normal adult brain rarely
appear to fluctuate, and nearly all brain regions have been shown
to have high levels of GSK3b, although there are marked regional
differences of GSK3b mRNA levels in the human brain [13].
However, during development the levels of GSK3b in the brain do
change, with the level of expression peaking during embryonic
development. In addition, previous investigations have shown that
in post-mortem tissues from individuals with schizophrenia the
levels of GSK3b are decreased [11]. In addition, GSK3b activity is
also dependent on its phosphorylation status. GSK3b is constitu-
tively active, but phosphorylation at its serine-9 site decreases its
activity. Several therapeutic drugs have been shown to increase
GSK3b serine-9 phosphorylation and inhibit its activity, such as
lithium [9,14] and pilocarpine [15], as well as a host of other
agents such as growth factors, neurotransmitters, cytokines,
anesthetics, and hormones [16,17]. Thus, the anatomical distri-
bution of GSK3b in different brain regions, its overall levels, and
the phosphorylation status at serine-9 of GSK3b likely all affect its
physiological actions.
GSK3b is also involved in numerous signaling cascades which
can impact many biochemical processes, thus its activity must be
finely regulated. In fact, the regulation of GSK3b is multi-tiered.
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at its Ser9 site. Its association with other proteins, such as those of
the Wnt signaling pathway, can also affect GSK3b activity
[18,19]. Furthermore, it was shown that GSK3b activity is
dependent on its subcellular distribution [20]. GSK3b has been
reported to exist in the cytosol [21], the nucleus [22], and the
mitochondria [23,24]. Thus, intracellular localization can affect
the activity of GSK3b because it dictates its accessibility to various
cell compartment-specific substrates. Interestingly, very little is
known about the intracellular distribution of GSK3b in the brain.
Although there are studies which have investigated the
neuroanatomical distribution of GSK3b in the brain by light
microscopy [4,5,25–31], nearly nothing has been described about
GSK3b visual localization in the brain at the ultrastructural level.
Using immunohistochemistry for the detection of GSK3b and
phospho-serine-9 GSK3b in combination with light microscopy
and transmission electron microscopy, we show the differential
expression of GSK3b and phospho-serine-9 GSK3b within
different brain regions and their intracellular distribution within
different subcellular compartments.
Materials and Methods
Ethics Statement
All animal housing, care, and experimental procedures were
done in accordance with, and approved by, the University of
Alabama at Birmingham Institutional Animal Care and Use
Committee (IACUC) guidelines. Mice were euthanized according
to an approved IACUC protocol.
Immunohistochemistry
Six adult male C57BL6 mice (10 to 12 week old) were used in
this study. Mice were euthanized by decapitation and the brains
were immediately removed, quickly rinsed in cold 0.1M phosphate
buffer (PB), and fixed by immersion in a 4% paraformaldehyde
and 0.1% glutaraldehyde in PB solution, pH 7.4, at 4uC
overnight. The brains were then sectioned in the coronal plane
on a vibratome and 40 mm free-floating sections were obtained.
The sections were kept in PB at 4uC until processed for
immunohistochemistry.
For the immunohistochemical localization of GSK3b and
phospho-serine-9 GSK3b (pSer9GSK3b) free-floating sections
were rinsed in phosphate buffered saline (PBS), quenched in 1%
sodium borohydride in PBS for 15 minutes, rinsed multiples times
in PBS, and the endogenous peroxide was blocked in a solution of
1.5% hydrogen peroxide in PBS for five minutes. After rinsing in
PBS, non-specific binding sites in the sections were blocked with
2% normal goat serum in PBS for 30 minutes. The sections were
then incubated for 72 hours at 4uC in a 1:500 dilution of a
monoclonal rabbit GSK3b antibody, or a 1:100 dilution of a
polyclonal rabbit pSer9GSK3b antibody (Cell Signaling, Danvers,
MA). For the GSK3b antibody two types of controls were
performed: some sections were incubated in the absence of
primary antibody, while others were incubated with the GSK3b
antibody pre-adsorbed with two micrograms of GSK3b blocking
peptide (Cell Signaling). For the pSer9GSK3b antibody the
immunohistochemical controls consisted of sections incubated in
the absence of the primary antibody. After rinsing in PBS, all
sections were incubated with a biotinylated goat anti-rabbit
secondary antibody (Vector laboratories, Burlingame, CA) diluted
1:200 for 1 h at room temperature. Then, sections were rinsed in
PBS and incubated for 30 minutes with an avidin-biotinylated
horseradish peroxidase complex (Vectastain ABC system, Vector
Laboratories). After rinsing in PBS, the sections were developed in
a diaminobenzidine solution (10 mg/15 ml PBS; Sigma, St Louis,
MO) containing 0.03% hydrogen peroxide for 2–5 min to
visualize the reaction product. The sections were then rinsed in
PB and processed for light or electron microscopy.
Light Microscopy
Immunostained sections were mounted on Colorfrost/Plus
slides (Fisher, Pittsburgh, PA), air-dried overnight, dehydrated in
ascending series of ethanol, cleared in xylene and coverslipped
with Eukitt mounting media (O. Kindler, Germany). Sections were
viewed and photographed using a Nikon DS-Fi1 color digital
camera coupled to a Nikon Eclipse 50i. Images were converted to
grey scale and adjusted for brightness and contrast using Corel
PhotoPaint 12 (Corel Corporation, Ottawa, Canada). Photomon-
tage and lettering were done using CorelDraw 12.
Electron Microscopy
Immunostained sections were rinsed in PB and immersed in a
solution of 1% osmium tetroxide in PB for 1 hour, then rinsed in
PB and gradually dehydrated on series of ethanol from 30% to
70%. After that, the sections were stained with a solution of 1%
uranyl acetate in 70% ethanol for 1 hour and further dehydrated
in ethanol. After dehydration was completed the sections were
cleared in propylene oxide and infiltrated with Epon resin
overnight at room temperature. The following day the sections
were flat-embedded in new Epon resin and allowed to polymerize
in an oven at 60uC for 72 hours. Selection of regions of interest for
electron microscopy was performed by visualizing the flat-
embedded sections on a Nikon Eclipse 50i light microscope,
carefully identifying anatomical regions and re-dissecting these
regions for ultramicrotomy. Ultrathin sections (90 nm thick) were
obtained using a Leica EM UC6 ultramicrotome (Leica Micro-
systems, Wetzlar, Germany), mounted on copper grids and
observed and photographed using a Hitachi TEM model H-
7650-II (Hitachi, Japan) equipped with an AMT digital camera
(Danvers, MA). Photomontage and lettering was done as for light
microscopy.
Western-Blot
For pSer9GSK3b antibody staining controls only, mouse brain
homogenates from two mice (n=1 control, n=1 pilocarpine) were
used to test the specificity of the antibodies used in the study.
Western blot assays were first performed for both GSK3b and
GSK3a. In addition, to confirm the specificity of the pSer9GSK3b
antibody, serine-9 phosphorylation of GSK3b in the mouse brain
was induced by the intraperitoneal injection of pilocarpine
(30 mg/kg body weight) diluted in saline [15]. After 15 minutes,
brains were dissected and homogenates were obtained and
immunoblotted with both pSer9GSK3b and GSK3b antibodies.
Results
In the present study, we focused on the neuroanatomical and
intracellular distribution of GSK3b in the adult mouse brain using
immunohistochemistry for the detection of GSK3b in combina-
tion with light and electron microscopy. We first performed a light
microscopy study of the distribution of GSK3b in the adult mouse
brain to compare with previous studies published on the
distribution of GSK3b in other rodent species. After studying
the distribution and subcellular localization of the constitutively
active GSK3b, we proceeded to analyze the distribution and
subcellular localization of the inhibited form of GSK3b in the
brain by using a specific antibody against pSer9GSK3b at the light
and electron microscopy level.
GSK3b Subcellular Localization
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Immunohistochemistry in the Adult Mouse Brain
It was initially necessary to confirm the specificity of the
phospho-independent GSK3b antibody (Cell Signaling, catalog #
9315) used for this study. The GSK3b antibody was first used to
immunoblot mouse brain lysates (Figure 1A). As a further test of
specificity the antibody was also mixed with another separate
antibody for GSK3a (Cell Signaling, catalog #9338). Then, the
mixture of the two antibodies was incubated with a GSK3b
blocking peptide (Cell Signaling, catalog #1073) to specifically
bind to the GSK3b antibody and block it. This mixture was then
used to immunoblot the brain lysates (Figure 1A). Our results show
that the GSK3b antibody is specifically blocked by the peptide
while GSK3a is not blocked by this peptide. In addition, when
brain lysates were immunoblotted with the GSK3b antibody
alone, only the one GSK3b protein band was evident on the
autoradiography film, further indicating that this antibody does
not recognize other proteins. As further tests of antibody
specificity, immunostaining was performed in parallel sections of
the mouse brain to compare the staining obtained with the
GSK3b antibody alone, preadsorption of GSK3b with the
blocking peptide, and omission of the primary antibody. Our
results showed that GSK3b strongly labels neurons in the cortex
and striatum (see pSer9GSK3b results and figures) whereas in an
adjacent section that was processed with the peptide-preadsorbed
antibody no immunostaining was observed (Figure 1C). Addition-
ally, incubation with a non-specific rabbit IgG, or omission of the
primary antibody produced no staining (data not shown).
Together these results confirmed the specificity of GSK3b
immunolabeling and validated the use of this antibody for our
studies at the light and electron microscope.
Our study commenced with a light microscopic examination of
the phospho-independent GSK3b immunohistochemical labeling
in adult male C57BL6 mouse brain. The most salient feature
under light microscopy was the abundance of GSK3b immuno-
reactivity in neuronal populations throughout multiple brain
Figure 1. GSK3b specificity and distribution in the cortex. A) Immunoblot of mouse brain lysates showing the specificity of the antibody used.
The left column shows the presence of 2 bands, an upper band (GSK3a) and a lower band (GSK3b), when there is no blocking peptide present (2).
However, in the presence of the GSK3b blocking peptide (+), the lower GSK3b band is specifically blocked while the upper GSK3a band is still present.
B–C) Immunohistochemistry specificity: GSK3b immunostaining (B) displays robust labeling in the cortex (ctx) and striatum (str), while there is no
staining in the corpus callosum (cc). Addition of the blocking peptide (C) produces complete abolition of the staining in these same regions. D)
GSK3b immunolabeling in the primary somatosensory cortex. Neuronal cytoplasm and the initial segment of the apical dendrites is strongly
immunolabeled (arrowheads). E) GSK3b labeled neurons in the piriform cortex also show clearly stained processes running laterally (arrowheads). F)
Image showing GSK3b-labeled neurons in the lateral entorhinal cortex (LEnt) and the pyramidal cell layer of the hippocampus (Py) separated by the
unlabeled external capsule (ec). G–H) Detail of labeled neurons in the lateral entorhinal cortex (G) and pyramidal cell layer of the hippocampus (H).
[d: dorsal; m: medial; Scale bars: 100 mm in B–C; 25 mm in E–F; 5 mm in D and G–H]
doi:10.1371/journal.pone.0008911.g001
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staining contrasted with the copious labeling of neuronal cells
within most neuronal subtypes and cell layers within the cortex
and hippocampus, as well as in many other brain regions. In the
following paragraphs we will describe the more salient features of
GSK3b distribution across the rostrocaudal extent of the adult
mouse brain.
In the cortex GSK3b is abundantly present from the most
rostral to the most caudal cortical areas. Many areas of the cortex
present immunolabeled cell bodies, but also clearly immuno-
stained processes, especially in the dorsal areas of the motor
cortex, dorso-lateral areas corresponding with the somatosensory
cortex (Figure 1D), and in the piriform cortex (Figure 1E). In some
areas such as the motor cortex, evident differences in staining
intensity were observed across the different cortical layers, with the
areas corresponding with layers I, III and V-VI showing more
intense labeling. A similar labeling pattern can also be seen in the
cells of the entorhinal cortex and the pyramidal cell layer of the
hippocampus (Figures 1F-H).
Throughout the hippocampus GSK3b immunoreactivity was
evident at low magnification with staining differences among
hippocampal layers (Figure 2A). The pyramidal neurons in the
cornu ammonis (CA) and the polymorphic layer of the dentate
gyrus exhibited particularly high levels of staining that contrast
with the lack of staining in adjacent areas such as the molecular
layer (Figure 2A). At higher magnification, the polymorphic layer
of the dentate gyrus contained high levels of GSK3b in both the
cell body and in the initial segment of processes (Figure 2B). Also,
closer inspection of labeling in the CA1 region (Figure 2C) reveals
multiple pyramidal neurons with high levels of GSK3b in both the
cell body and the dendrites. The most robust immunostaining of
the CA regions was apparent in the CA3, which again contained
high somatic and dendritic staining of GSK3b in numerous
pyramidal neurons (Figure 2D).
Other areas of the brain also presented prominent GSK3b
labeling, especially the striatum, the globus pallidus, thalamus, the
substantia nigra and some brainstem areas (Figure 3). In contrast,
hypothalamic nuclei presented less robust immunolabeling (not
shown). Within the striatum GSK3b labeling is prominently
present in cell bodies but not in the numerous fiber bundles that
cross this area of the brain (Figure 3A). Although striatal fiber
bundles and the corpus callosum are prominently unlabeled, some
scattered immunolabeled small cells are observed in some areas of
the corpus callosum, probably corresponding with glial cells.
Prominently labeled neurons are also observed in the globus
pallidus (not shown). Caudal to the striatum, the thalamic region
presents several strongly labeled nuclei, including the reticular and
geniculate nuclei (Figure 3B). The subthalamic nucleus is also
strongly labeled (Figure 3C) while adjacent hypothalamic areas
present only weakly labeled neurons. In the midbrain, the
substantia nigra and ventral tegmental area present GSK3b
positive neurons, the substantia nigra pars compacta being the most
strongly labeled area (Figure 3D). Also in this area, neurons of the
red nucleus are prominently labeled (Figure 3E). Finally, the
cerebellum presents layer specific immunolabeling; the granular
layer was virtually devoid of immunostaining, while the Purkinje
cell layer presents clusters of GSK3b-labeled neurons interspersed
with other clusters of unlabeled neurons. The molecular layer is
also labeled and some strongly stained Purkinje cell dendrites are
clearly seen (Figure 3F). Thus, high levels of GSK3b labeling were
found in all the brain regions examined. Furthermore, this
evaluation by light microscopy placed into context the subcellular
Figure 2. GSK3b labeling in the hippocampus. A) Low magnification image showing GSK3b labeling in different layers of the hippocampus.
This immunolabeling is especially robust in the Cornu Amonis (CA) subfields and in the dentate gyrus (DG). B) Detail of the dentate gyrus showing
labeling in the neurons of the polymorphic layer (arrows) and also in the granular layer (g). C–D) Detail of GSK3b immunolabeling in pyramidal cells
of CA1 (C) and CA3 (D) and in their processes (arrowheads). [Scale bars: 400 mm in A; 100 mm in B–D]
doi:10.1371/journal.pone.0008911.g002
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microscopy.
Subcellular Localization of GSK3b at the Electron
Microscope
Since the pattern of GSK3b labeling at the light microscopic
level was similar among the brain regions examined, we selected
one region (piriform cortex) to study in more detail at the electron
microscopic level (Figures 4A–F, and Figures 5A–E). GSK3b
labeling at the ultrastructural level was similar among the several
cases that were examined. Consistent with light microscopy,
GSK3b labeling was most evident in the soma and the dendritic
shafts of neurons (Figure 4F, 5D–E). There did not appear to be
differences in the staining pattern of cell bodies based on the
morphology of the neuron (pyramidal vs. non-pyramidal). GSK3b
labeling was abundant preferentially in the cytoplasm of neuronal
somata (Figure 4A–E, 5A–B). Closer inspection of the soma
revealed GSK3b concentrated on ribosomes, rough endoplasmic
reticulum (RER), and the outer membranes of mitochondria
(Figure 4B–F, 5A–E). Examination of dendritic shafts showed clear
labeling of GSK3b throughout the cytoplasm, on ribosomes, and
on the outer mitochondrial membrane (Figure 4F, 5C–D).
Interestingly, dendritic mitochondria showed more robust GSK3b
staining than mitochondria in the neuronal cell body (compare
Figure 4E to 4F or 5E). In the neuropil, dense immunolabeling was
found in postsynaptic densities in both dendrites and dendritic
spines.
In neuronal profiles, labeling was consistently absent from the
nucleus, myelinated and unmyelinated axons (Figure 4B, 5C),
axon terminals (Figure 4F) and lysosomes (Figure 4B). Interest-
ingly, this phospho-independent GSK3b staining was not evident
in the oligodendrocytes, endothelial cells or microglia (Figure 5A,
C). The only type of glial cells that presented labeling was
astrocytes. In astroglial somata, the labeling was present on similar
Figure 3. GSK3b labeling in subcortical regions and in the cerebellum. A) GSK3b-labeled neurons in the striatum (arrows). Note that fiber
bundles crossing this area are devoid of immunolabeling (outlined stars). B–E) Labeled neurons (arrows) in the geniculate nucleus of the thalamus (B)
appear in ‘‘rows’’ strongly immunostained with clear nucleus and almost no processes visible. In the subthalamic nucleus (STh), labeled neurons are
surrounded by labeling that may correspond with small processes (C). The same type of labeling is observed in the substantia nigra (SN) where
neurons present strongly stained cell bodies (D). The red nucleus (E) shows GSK3b positive neurons (arrows) interspersed with negative fiber
bundles. F) In the cerebellum, Purkinje cells are GSK3b immunolabeled (arrows). There is strong labeling in the molecular layer (ml), while the granule
cell layer (gcl) is almost devoid of staining. Note also that Purkinje cell dendrites in the molecular layer are strongly labeled (arrowheads). [cp:
cerebellar peduncle; Scale bars: 50 mm in all images]
doi:10.1371/journal.pone.0008911.g003
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glial processes throughout the neuropil and in astrocytic end feet
on capillaries was often apparent (Figure 5B–D). Thus, the
examination by EM revealed the specific subcellular distribution of
the GSK3b in the brain, which was not fully known.
Distribution of pSer9GSK3b at the Light and Electron
Microscope
Although GSK3b is a constitutively active kinase, its activity is
subject to modulation, and phosphorylation at its serine-9 residue
is well recognized as one of the primary regulatory modifications
[32–36]. Hence, phosphorylation of serine-9 correlates with
reduced GSK3b activity. The goal was to examine the distribution
of the latent pSer9GSK3b in the brain. The antibody specific for
pSer9GSK3b (Cell Signaling, catalog #9336) was initially tested
for its specificity by immunoblot analysis. Basal pSer9GSK3b was
clearly visible in mouse brain lysate immunoblots (Figure 6A), and
treatment of mice with pilocarpine, which increases phosphory-
lation at serine-9 [15], resulted in a noticeable increase in
pSer9GSK3b immunoreactivity in western-blots (Figure 6A).
pSer9GSK3b was also blotted in parallel with the total GSK3b
antibody to confirm that the phospho-specific antibody recognized
the correct molecular weight of GSK3b (approximately 47 kDa),
which it did (Figure 6A). Although the manufacturer of the
pSer9GSK3b antibody, Cell Signaling, does mention the possi-
bility of minor cross reactivity of this antibody with the
phosphorylated GSK3a isoform, our immunoblot analysis showed
that this antibody reacts with pSer9GSK3b to phosphorylated
GSK3a at a 9.7 to 1 ratio, respectively, in an overexposed blot.
Thus phospho-GSK3a labeling is inconsequential. Together, these
Figure 4. Electron microscopy images of GSK3b labeling in the piriform cortex. A) Two adjacent labeled neurons. B) Detail of neurons in A.
GSK3b labeling is located in the rough endoplasmic reticulum (outlined arrows) and free ribosomes (outlined stars). C) Detail of neurons in A
showing labeled mitochondria (black arrows), abundant labeled free ribosomes (outlined stars), and also labeled rough endoplasmic reticulum
(outlined arrows). Note also the labeling in dendrites (d). D) Another labeled neuron with strong cytoplasmic staining. Dendrites (d) are also labeled.
E) Detail of neuron in D showing strongly labeled rough endoplasmic reticulum (outlined arrow), free ribosomes (outlined stars) and also labeling on
the outer surface of the mitochondria (black arrows). Note also unlabeled myelinated axons (black star). F) High magnification image of two dendrites
(d). GSK3b staining is conspicuously present on the postsynaptic density (outlined arrowheads). Cytoplasmic elements including the outer membrane
of mitochondria (black arrows) are also labeled. However, no labeling is present in axon terminals (at). [N: nucleus; Scale bars: 4 mm in A–D; 1 mmi n
B–C and E–F]
doi:10.1371/journal.pone.0008911.g004
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and indicated that it could be used for the immunohistochemical
analysis at the light and electron microscope.
The rostrocaudal localization of pSer9GSK3b immunolabeling
was first analyzed at the light microscope, and then representative
brain areas were selected for the subsequent analysis of subcellular
distribution using electron microscopy. At the light microscope
pSer9GSK3b was evident in the rostrocaudal extent of the brain,
but compared to the phospho-independent GSK3b, the
pSer9GSK3b staining pattern was markedly different and less
intense with far fewer pSer9GSK3b-positive cells. In contrast with
the phospho-independent GSK3b staining, the pSer9GSK3b
staining was abundantly present in glial cells and glial processes
in all brain regions. Most of the labeled glial cell bodies
corresponded with non-reactive microglia cells, which also
displayed pSer9GSK3b-labeled processes (Figures 6B-C insets,
6G–H). Labeled neurons were present in discrete areas, mostly in
cortical regions and more abundantly in superficial layers of the
cortex (Figure 6B–D). For example, in the motor and somatosen-
sory cortex pSer9GSK3b-labeled neurons were more abundant in
superficial layers (Figure 6B) and their abundance progressively
diminished, with the deeper layers almost devoid of labeled
neurons (Figures 6B–C). Here the immunolabeling was mainly
confined to non-reactive microglia cells. pSer9GSK3b neuronal
labeling appears mainly in the cell body, and labeling of the
neuronal processes is not clearly evident (Figures 6B, 6D). In some
other cortical areas such as the piriform cortex (Figure 6D)
pSer9GSK3b-labeled neurons are interspersed with labeled
microglia cells (Figure 6D). In the hippocampus, in contrast with
what was observed for GSK3b, pSer9GSK3b immunolabeling
was almost exclusively observed in microglia cell bodies and glia
processes (Figures 6E–H). Other brain areas presented a similar
pattern of pSer9GSK3b labeling at the light microscope, with
abundant labeling of non-reactive microglia and scarce labeling of
neurons. These regions include the striatum (Figure 6C and 6C
inset), the thalamus, the substantia nigra, and other midbrain and
brainstem nuclei. The cerebellum presented labeling in Purkinje
cells as well as abundant microglia labeling (not shown).
Due to the presence of different patterns of staining at the light
microscope (i.e. regions with neuronal and glia labeling versus
regions presenting almost exclusively glia staining), several
representative areas of the brain were selected for closer analysis
by the electron microscope, including the piriform and motor
cortex, and the striatum. Overall, the subcellular localization of
pSer9GSK3b in the immunolabeled cells was similar in all these
regions with frequent presence of labeling in free ribosomes,
endoplasmic reticulum, and in the nuclei of microglia and neurons
(Figure 7A–E). In addition, astrocytic processes were frequently
observed containing pSer9GSK3b labeling (Figure 7E–F). In
contrast with what was observed for GSK3b, very scarce
pSer9GSK3b immunolabeling was observed in mitochondria
(Figure 7A, E–F). Thus, at the ultrastructural level, the distribution
Figure 5. Electron microscopy images of GSK3b labeling in the piriform cortex. A) Partial image of a neuron (n) with an adjacent
oligodendrocyte (o). The cytoplasm of the neuron presents abundant and strongly labeled rough endoplasmic reticulum (outlined arrows) and free
ribosomes (outlined stars). In contrast, the adjacent oligodendrocyte (o) is completely devoid of immunostaining. The electron-dense appearance of
the oligodendrocyte cytoplasm is not due to GSK3b labeling [this is the typical appearance of an unlabeled mature oligodendrocyte cytoplasm]. B)
Image of a labeled astrocyte (a) adjacent to a labeled neuron (n). Both the small cytoplasm of the astrocyte and the abundant cytoplasm of the
neuron present labeling in the rough endoplasmic reticulum (outlined arrows) and in free ribosomes (outlined stars). C) A labeled astrocytic process
(a) is surrounding an unlabeled blood vessel (v). The basement membrane and endothelial cell are devoid of labeling. A dendrite (d) and a
postsynaptic density (white arrowhead) are also labeled. Note that myelin is completely devoid of immunostaining (black star). D) Detail image of a
GSK3b dendrite (d). Strongly labeled mitochondria (black arrows) and free ribosomes (outlined stars) are also seen. E) Examples of two synapses. One
is a GSK3b-labeled synapse (white arrowhead), while the other synapse is unlabeled (black arrowhead). Note the rich cytoplasmic stain in the dendrite
(d) and the staining of the outer mitochondrial membrane (black arrow). [N: nucleus; Scale bars: 2 mm in A–B; 1 mm in C–E]
doi:10.1371/journal.pone.0008911.g005
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of the pSer9GSK3b antibody used and its comparison with an immunoblot for GSK3b. For both blots, brain samples from control (2) and pilocarpine-
treated (+) animals were used. Both antibodies detected only one protein band of equal molecular weight on the immunoblots. The pSer9GSK3b
antibody detected the basal pSer9GSK3b and the pilocarpine-induced increase in pSer9GSK3b. B) pSer9GSK3b labeling in the motor cortex. Note the
abundance of labeled neurons (arrows) in the superficial layers while neuronal labeling decreases progressively in deeper layers where microglia
labeled cells are more frequent. B-inset: detail of a labeled microglia cell located in the deeper layers of the motor cortex showing staining in the cell
body and processes. C) pSer9GSK3b labeling in cortical and subcortical areas. Low magnification image showing most of the labeling in microglia
(arrowheads) both in the somatosensory cortex (ctx) and in the striatum (str). C-inset: Detail of a labeled microglia cell in the striatum showing
staining in the cell body and fine processes. D) Image of the piriform cortex where pSer9GSK3b labeling is present both in neurons (arrows) and in
microglia cells (arrowheads). Note that positive neurons are concentrated in one narrow strip, while microglia cells are present interspersed with
labeled neurons and also in more medial and lateral areas. E) Low magnification image of pSer9GSK3b labeling in the hippocampus. All hippocampal
areas present almost exclusively glial staining. The boxed area is shown as a detail in G. F) Image of pSer9GSK3b staining in different layers of the
dentate gyrus showing immunolabeled microglial cells (arrowheads). Note the absence of immunostaining in neurons of the granule cell layer (g).
The boxed area is shown in detail in H. G) Detail of a labeled microglia cell in the stratum oriens of the hippocampus showing intense
immunostaining in the cell body and processes. H) Detail of a labeled microglia cell in the granule cell layer of the dentate gyrus showing intense
immunostaining in the cell body and processes. [CA1, CA2, CA3: Cornu Amonis subfields; cc: corpus callosum; ctx: cortex; d: dorsal; DG: Dentate
Gyrus; L: lateral; m: medial; mol: molecular layer of the DG; Or: stratum oriens; p: polymorphic layer of the DG. Str: striatum. Scale bars: 100 mmi nE ;
25 mm in B–D and F, 5 mm in B-inset, C-inset and G–H]
doi:10.1371/journal.pone.0008911.g006
GSK3b Subcellular Localization
PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8911Figure 7. Electron microscopy images of pSer9GSK3b labeling in cortical and subcortical areas. A) pSer9GSK3b labeling in a neuron in
the piriform cortex. The labeling is located in the rough endoplasmic reticulum (outlined arrows), free ribosomes (stars) and the outer mitochondrial
membrane (black arrow). Note the strong staining in a cluster of free ribosomes in A inset. B) pSer9GSK3b immunolabeling in a microglia cell in the
piriform cortex. Staining is present in the rough endoplasmic reticulum (outlined arrows) as well as in free ribosomes (stars). B inset shows a detail of
the labeling present in this cell. C) pSer9GSK3b labeling in another microglia cell in the piriform cortex. In this case labeling is prominently present in
the nucleus (arrowheads) while the cytoplasmic labeling is restricted to a small portion of the rough endoplasmic reticulum (outlined arrow). C inset
shows a detail of the labeling present in the nucleus (arrowhead) and the rough endoplasmic reticulum (outlined arrow) in the proximity of the outer
nuclear membrane. D) pSer9GSK3b staining in a microglia cell in the striatum. Labeling is prominent in clusters of free ribosomes (stars) in the
cytoplasm as well as in the process (see D inset). E) Photomicrograph of pSer9GSK3b staining in a neuron in the motor cortex. Note the prominent
labeling in the nucleus (arrowheads). Labeling is also present in the rough endoplasmic reticulum (outline arrows, see also E Inset), as well as in
clusters of free ribosomes and in the outer membrane of one mitochondria (black arrow). Note also the presence of an astrocytic process (a) showing
immunolabeling in free ribosomes (star). F) Detail of an astrocytic process (a) showing pSer9GSK3b immunolabeling in rough endoplasmic reticulum
(outlined arrow), free ribosomes (star) and mitochondria (black arrows). [Lf: Lipofuscin body; N: nucleus; Scale bars: 1 mm in A–C, E; 0.5 mmi nD ;
0.25 mm in B inset, C inset; 0.1 mm in D inset]
doi:10.1371/journal.pone.0008911.g007
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the phospho-independent GSK3b staining.
Discussion
GSK3b plays a diverse role in normal brain function, and its
dysregulation is believed to underlie some psychiatric disorders
and neurodegenerative diseases [16,37,38]. In light of the critical
role of GSK3b in the CNS, several groups have studied the
expression pattern and activity of endogenous GSK3b in the brain
by immunohistochemistry and light microscopy during brain
development, in brain disease processes, and in response to various
stimuli [4,5,25–31]. In this regard the light microscopy data
reported in the present study is supportive of many of the earlier
reports. However, to further elucidate the distribution of GSK3b
at the subcellular level, the expression of this kinase was also
evaluated by electron microscopy. Although Hoshi et al. [39,23]
originally described expression of GSK3b in brain mitochondria
by electron microscopy, a detailed analysis of GSK3b expression
at the ultrastructural level has not been reported previously. Thus,
the main goals of this study were to corroborate the distribution of
GSK3b in the brain, and to examine in detail the subcellular
distribution of this protein.
Initial examination by light microscopy revealed that GSK3b is
expressed in brain neurons throughout all the rostrocaudal extent
of the adult mouse brain. Overall, the distribution observed in our
light microscopy study mostly concurs with findings in previous
studies. Takahashi et al. [25] had originally conducted an
extensive immunohistochemical survey of GSK3b expression in
the developing and adult rat cerebellum. In their study, in which
GSK3b is referred by its other name, t protein kinase I, they
reported GSK3b expression in axonal fibers of the axonal tract
and in the granular layer. Expression of which they reported
decreased during later stages of development [25]. They also
found that GSK3b immunostaining in the molecular layer
increased in later stages of development, and the Purkinje cells
in the Purkinje cell layer had staining mainly in their cytoplasm
[25]. These findings were subsequently confirmed by Leroy and
Brion [28]. In our study we have found that in the mature mouse
brain, the Purkinje cell layer and the molecular cell layer (where
the dendritic processes of Purkinje cells end) present strong
GSK3b labeling, while the granular cell layer was devoid of
immunostaining and non-axonal staining was observed. These
data are generally in accordance with previously reported studies,
however Takahashi et al [25] and Leroy and Brion [28] reported
some immunostaining in the granular cell layer of the adult rat
brain. This discrepancy could be due to several reasons including a
difference in species (mice in our study versus rats), gender (i.e. the
studies in rat do not state if they have used male or female
animals), or age of the animals used. In addition, it was previously
reported that in the adult rat brain there was strong staining in the
hippocampus in the CA and dentate gyrus regions, the deeper
cortical layers, thalamic nuclei, and the substantia nigra pars
compacta [28]. However, our findings indicated a lack of GSK3b
staining in most hypothalamic areas of the adult mouse brain,
whereas previously strong labeling of GSK3b was noted in this
region of the brain in the adult rat [28]. This difference could also
potentially reflect some variance between the two species or
perhaps a gender difference. Overall, the present light microcopy
data mostly concurred with previous findings on GSK3b
localization in the brain, and was meant to establish a frame of
reference for examination of GSK3b at the subcellular level.
GSK3b immunolocalization was also examined by electron
microscopy to scrutinize its subcellular distribution. The most
salient feature is the abundance of GSK3b immunostaining in the
cytosol of the neuronal soma, dendritic shaft, dendrites, and
dendritic spines, but no GSK3b labeling was observed in axons.
Within neurons GSK3b labeling was clearly present in the rough
endoplasmic reticulum (RER), free ribosomes and in the outer
membrane of mitochondria. Furthermore, we also found clear
presence of GSK3b within astrocytes, especially on their RER,
free ribosomes, mitochondria, and in astrocytic processes. In
contrast, other glial types, such as the oligodendrocytes and
microglia showed little evidence of GSK3b labeling. Although
several studies have already noted GSK3b signaling activity in
isolated astrocytes [40–42], and elevated staining of phospho-
serine-9 GSK3b in astrocytes by light microscopy has been
reported in cases of human tauopathies [43], other immunohis-
tochemical studies [28–30], could not detect, or did not report,
staining of GSK3b in astrocytes by light microscopy. However,
our data shows that GSK3b labeling is clearly present in astrocytes
at the electron microscope level and GSK3b appears in several
subcellular structures such as the RER, ribosomes and mitochon-
dria, albeit at much lower levels than in neurons.
Electron microscopy data of the intracellular distribution
GSK3b in neurons revealed that GSK3b is expressed in the
mitochondrial membranes, and robust GSK3b labeling was found
on ribosomes and the rough endoplasmic reticulum. In the
mitochondria, GSK3b was previously reported to be resident in
the mitochondrial membranes of cultured SH-SY5Y cells [24],
and activated GSK3b is believed to regulate mitochondrial
metabolic output [23,44], mitochondrial motility [45], and
mitochondria-linked apoptosis signaling [46,44]. In addition,
GSK3b signaling is known to impact protein translation through
its phosphorylation of eukaryotic initiation factor 2B [47] possibly
at the vicinity of the ribosomes and the RER. Increased GSK3b
activity is also known to accentuate ER stress [48]. Thus, the
strong labeling of GSK3b at the RER and ribosomes provides
further support of its known signaling activities at these sites. In
contrast to the robust staining of GSK3b in the endoplasmic
reticulum and the mitochondria was the lack of GSK3b staining in
brain cell nuclei under both light and electron microscopy.
Previously it has been shown by immunoblot analysis that GSK3b
is present in biochemically separated nuclear fractions of normal
mouse brain [20]. However, through various pharmacological
treatments and molecular methods it was determined in SH-SY5Y
cells that the presence of GSK3b in the nucleus is transient [22],
and its transit between the cytosol and the nucleus is highly
dynamic [49]. Thus, when isolated brain cell nuclei from healthy
brain tissues are examined ‘‘en masse’’ by immunoblot analysis
GSK3b can be detected in the nucleus, but GSK3b staining in
individual healthy neuronal nuclei by microscopy may not be
readily visible. Furthermore, GSK3b is known to accumulate in
the nucleus upon activation of apoptosis signaling [50,22].
Therefore nuclear GSK3b labeling in the brain may be more
evident in dying neurons.
Another interesting finding was the noticeable GSK3b labeling
of some postsynaptic densities. There is emerging evidence that
GSK3b affects neuronal synaptic plasticity and is involved in
synaptic activities [51–54]. Previously, GSK3b had been detected
in synaptosomal fractions [51,54] and in the dendrites of cultured
hippocampal neurons [53]. Peineau et al. [53] have reported that
GSK3b mediates both N-methyl-D-aspartate receptor-dependent
long-term potentiation and long-term depression. Furthermore,
Zhu and colleagues [52] have shown that GSK3b activation can
impair the synapse ultrastructure in the tetanized CA3 region of
the rat hippocampus, and inhibitors of GSK3b can restore the
synapse to its normal morphology. Our report shows that GSK3b
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devoid of GSK3b, this evidence clearly indicates that GSK3b is
located in the synapses and also that there is some degree of
specificity of GSK3b signaling at different synapses, which
requires further exploration.
Following our findings with the phospho-independent GSK3b
antibody, it was surprising to see a marked difference of the
pSer9GSK3b immunolabeling. For example, cell types, such as
the microglia, which showed no evidence of the phospho-
independent GSK3b staining, presented with clear and robust
pSer9GSK3b staining. One possibility for the discrepant labeling
could be that phosphorylation at serine-9 of GSK3b may partially
block the immunoreactivity of the phospho-independent GSK3b
antibody, thus regions with a high concentration of pSer9GSK3b
may appear as devoid of GSK3b. Nonetheless, the presence of the
serine-9-phosphorylated GSK3b within the microglia indicates
that GSK3b must be present within these cell types. Previously,
Yuskaitis and Jope [55] reported that GSK3b signaling in
microglia promotes the lipopolysaccharide-induced production of
interleukin-6 and expression of inducible nitric oxide synthase, and
regulates microglial migration, all of which can be blocked by
GSK3b inhibitors. Our findings show that GSK3b signaling is
resident within microglia in discreet areas on free ribosomes, the
ER, and in the nuclei of some cells. However, under normal
conditions GSK3b in resting microglia is mostly in its less
activated, serine-9-phosphorylated state.
pSer9GSK3b-labeled neurons were also evident by light and
electron microscopy, but this labeling was far less pronounced than
the phospho-independent GSK3b labeling. The clearest
pSer9GSK3b staining was in the superficial layers of the cortex,
with diminishing staining in the deeper layers. Within the stained
neurons there was pSer9GSK3b labeling on the ribosomes on the
ER, and interestingly, inside the nuclei of some neurons. Previous
findings by western blot analysis of total mouse brain homogenates
[20] noted a paucity of nuclear serine-9-phosphorylated GSK3b,
but the present results indicate that there are clear regional
variations in these levels.
Another well-known GSK3b phosphorylation site is at its
tyrosine-216 residue. Active GSK3b is phosphorylated on
tyrosine-216 [56], and phospho-tyrosine-216 antibodies are
sometimes used for labeling activated GSK3b signaling. Our
attempts to immunohistochemically stain brain sections specifically
for pTyr216GSK3b were unsuccessful as many of the antibodies
that we tested also showed strong and equivalent reactivity to the
tyrosine-phosphorylated GSK3a isoform, or yielded high back-
ground staining that was unusable for immunohistochemistry at
the electron microscope. Nevertheless, the revelation that there are
brain areas with strong basal pSer9GSK3b labeling does indicate
that not all pools of GSK3b are equivalently activated, and that
the activation state of GSK3b can vary widely throughout
different brain regions, cell types, and cellular subfractions.
In conclusion, our light microscopy study of GSK3b mostly
corroborated previous immunohistological analyses of GSK3b
distribution in the brain. However, no previous study had
analyzed in detail the subcellular localization of GSK3b in the
brain. The presence of GSK3b within various intracellular
compartments was previously deduced through biochemical
studies; however, the presence of GSK3b in these compartments
was not confirmed by visualization of the protein in these
structures. The present study now visually demonstrates in detail
the location of GSK3b at the subcellular level in neurons and
astrocytes, confirming previous findings of biochemical studies.
The specific intracellular distribution of GSK3b within these brain
cells and at selective neuronal synapses opens some new avenues of
exploration of this kinase.
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